Sima Rozati, MD, PhD

Articles

When to Consider Allogeneic Transplant in CTCL & Clinical Pearls for Community Providers

July 18th 2025

Panelists discuss how stem cell transplantation is considered primarily for younger patients or aggressive CTCL variants, balancing timing, remission status, and potential risks, while also emphasizing the value of early referral and specialized guidance for advanced disease.

Clinical Perspectives: When to Revisit a Prior Therapies in Mycosis Fungoides and Sézary Syndrome

July 18th 2025

Panelists discuss how decisions about reintroducing previous therapies for CTCL are based on prior tolerance, current disease state, and the reason for stopping treatment, with flexibility to recycle effective agents when appropriate.

Monitoring Mogamulizuma: Managing and Differentiating Drug vs. Disease-Related Rash

July 11th 2025

Panelists discuss how to differentiate Mogamulizumab-associated rash from cutaneous T-cell lymphoma (CTCL) using clinical clues, biopsy findings, and molecular studies, and how treatment may be modified based on rash severity and characteristics.

Personalizing Care: Treatment Decisions in Sézary Syndrome

July 11th 2025

Panelists discuss how to sequence and personalize therapy for Sézary syndrome, with Mogamulizumab often used as first-line treatment due to potential for durable remission, followed by HDAC inhibitors, photopheresis, or Alemtuzumab depending on disease progression and transplant planning.

Expert Perspectives: Combination Therapies in Advanced-Stage MF

July 2nd 2025

Panelists discuss how to integrate skin-directed therapies with systemic treatments for CTCL, emphasizing individualized strategies based on disease compartment, cautious layering of treatments, management of bacterial colonization (especially Staph aureus), and use of adjunctive measures like bleach baths for optimizing skin health.

Treatment Challenges in Advanced Mycosis Fungoides: High Blood Burden or Nodal Disease

July 2nd 2025

Panelists discuss how to manage advanced-stage mycosis fungoides with nodal or visceral involvement by adapting treatments typically used for peripheral T-cell lymphoma, including single-agent chemotherapy and HDAC inhibitors, while accounting for long-term toxicities and unique dose considerations due to patient fragility and tumor biology.

Strategic Sequencing in Advanced Mycosis Fungoides: Choosing Between Immunomodulatory, HDAC, and Targeted Therapies

June 25th 2025

Panelists discuss how individualized treatment plans must consider disease location, drug access, comorbidities, and newer therapies like HDAC inhibitors and immune checkpoint inhibitors, while emphasizing the importance of managing expectations and monitoring side effects.

Advanced-Stage Mycosis Fungoides: Navigating Treatment Decisions Amid a Complex Therapeutic Landscape

June 25th 2025

Panelists discuss how treatment goals and selection for advanced-stage cutaneous T-cell lymphoma depend on disease compartmentalization, with therapies like brentuximab vedotin and mogamulizumab being used based on specific disease characteristics and toxicity profiles.

Monitoring Response in Early-Stage Mycosis Fungoides & Importance of Patient Education

June 18th 2025

Panelists discuss how careful patient monitoring, education, and expectation management are essential in evaluating the effectiveness of skin-directed therapies, emphasizing routine assessments, treatment compliance, and the need for patience due to varying response times.

Other Treatment Strategies in Early-Stage Mycosis Fungoides: TSEBT, Localized Radiotherapy, Phototherapy and Combination Approach

June 18th 2025

Panelists discuss how electron therapy—both spot and total skin electron beam—is used to manage extensive or refractory skin involvement and palliate symptoms in CTCL patients.

Collaborating With Dermatologists: Coordinating Skin-Directed Therapy and Follow-Up in CTCL

June 10th 2025

Panelists discuss how multidisciplinary collaboration between dermatologists and oncologists helps optimize personalized treatment plans by integrating skin-directed and systemic therapies.

Managing Early-Stage Mycosis Fungoides: Treatment Goals and Topical Therapy Selection

June 10th 2025

Panelists discuss how therapeutic goals for early-stage CTCL focus on symptom control with skin-directed therapies, avoiding systemic chemotherapy due to long-term toxicity and poor outcomes.

Understanding CTCL Staging: From Limited Mycosis Fungoides to Advanced Disease

June 4th 2025

Panelists discuss how early-stage CTCL is defined using TNMB staging criteria, the typical presentation of patients at various stages, and the implications for treatment approaches.

Cutaneous T-Cell Lymphoma Insights: Distinguishing MF and SS, and Recognizing Early-Stage Clues

June 4th 2025

Panelists discuss how CTCL is diagnosed, distinguished between Mycosis Fungoides and Sézary Syndrome, and why early-stage disease is often misdiagnosed due to its resemblance to benign skin conditions.